FDA MedWatch: saquinavir/ritonavir (ritonavir boosted saquinavir) drug interaction wi

  1. 0
    MedWatch - The FDA Safety Information and Adverse Event Reporting Program

    Roche and FDA notified healthcare professionals about an important drug
    interaction warning. Drug-induced hepatitis with marked transaminase
    elevations has been observed in healthy volunteers receiving rifampin 600 mg
    once daily in combination with ritonavir 100 mg/saquinavir 1000 mg twice
    daily (ritonavir boosted saquinavir). Roche advises prescribers that
    Rifampin should not be administered to patients also receiving
    saquinavir/ritonavir (ritonavir boosted saquinavir) as part of combination
    antiretroviral therapy (ART) for HIV infection.

    Read the complete MedWatch 2005 safety summary, including a link to the
    "Dear Healthcare Professional" letter, at:

    http://www.fda.gov/medwatch/SAFETY/2...5.htm#Invirase


Nursing Jobs in every specialty and state. Visit today and Create Job Alerts, Manage Your Resume, and Apply for Jobs.

A Big Thank You To Our Sponsors
Top